STAT+: Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more
Hello, everyone, and how are you today? We are muddling along, but the middle of…
Category: Pharmalot
STAT+: Drugmakers rely on ‘use codes’ to vastly expand the nature of their patent claims, STAT analysis shows
Amid debate over potential abuse of the U.S. patent system by the pharmaceutical industry, moves…
STAT+: U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals
A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds…
STAT+: Pharmalittle: We’re reading about an Express Scripts lawsuit against FTC, AMR deaths, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more
Rise and shine, everyone, another busy day is on the way. However, this is also…
STAT+: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams
The U.S. Food and Drug Administration has scolded AbbVie for making false and misleading claims…
STAT+: Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about a Roivant deal, limited access to medicines and more
The U.S. House of Representatives passed a bill by 306 to 81 votes to make…
STAT+: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries
Amid calls to expand access to medicines in low- and middle-income countries, a new analysis…
STAT+: Pharmalittle: We’re reading about a Maryland law governing 340B discounts, an obesity drug, and more
The largest U.S. pharmaceutical industry trade group and several drug companies lost a bid to…
STAT+: Pharmalittle: We’re reading about FDA inspections, Lilly insulin trial results, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Greece’s antitrust regulator probes Novartis over practices tied to a pricey eye drug
Greece’s antitrust regulator is investigating allegations that, over a nine-year period, Novartis paid doctors and…
STAT+: Pharmalittle: We’re reading about Medicare drug prices, a Sanofi MS pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
.jpg)
STAT+: Pharmalittle: We’re reading about Lilly cutting Zepbound’s price; Pfizer selling direct to consumers, and more
Good morning, everyone, and how are you today? We are just fine, thank you, especially…
STAT+: Pharmalittle: UCB selling a Chinese business, Tome layoffs, and more
Happy Monday, Pharmalittle family. Adam Feuerstein here, once again filling in for Ed. I have…
STAT+: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals
A U.S. government agency said that a planned move by Johnson & Johnson to alter…
STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more
Good morning, Pharmalittle fans! Adam Feuerstein here, filling in for Ed. I drink my morning…
STAT+: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?
As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether…
STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Medicare drug savings, Lilly warning doctors, and more
Top of the morning to you, and a fine one it is. The skies are…
STAT+: Pharmalittle: We’re reading about an AstraZeneca U.K. vaccine plant, Medicare premiums, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more
Rise and shine, everyone, another busy day is on the way. Our mascots, for instance,…
STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B
A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably…
STAT+: A U.K. trade group scolds Novo again — this time for remarks made by its CEO
Once again, Novo Nordisk has been admonished by a U.K. trade group for violating voluntary…
STAT+: Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: FDA scolds Bristol Myers over a misleading website for a cancer treatment
The U.S. Food and Drug Administration has scolded Bristol Myers Squibb for making false and…
STAT+: Pharmalittle: We’re reading about Roche plans for Flatiron, underwhelming Novo Nordisk earnings, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs
Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are…
STAT+: Pharmalittle: We’re reading about MDMA trials, weight loss drug availability, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more
Good morning, and happy Friday. This is Jonathan Wosen, West Coast biotech and life sciences…
.jpg)
STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed for the…
STAT+: Pharmalittle: We’re watching GLP-1 drug data in Alzheimer’s, a flu shot push for livestock workers, and more
Good morning, folks! The Dean of Pharmalittle University, Ed Silverman, is out on vacation. I…
STAT+: NIH loses suit over censoring social media comments made by animal rights advocates
In a boost for animal rights advocates, a U.S. appeals court ruled that a National…
STAT+: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a critical video, Roche fast-tracking an obesity pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more
And so, another working week will soon draw to a close. Not a moment too…